Stada Group
Yann Brun is an accomplished executive with extensive experience in global business development, regulatory affairs, and portfolio management in the pharmaceutical industry. Currently serving as Executive Vice President at STADA Group since October 2020, Yann leads global development and business strategies. In addition, Yann holds the position of Chairman of the Supervisory Board at BIOCEUTICALS Arzneimittel AG. Previous roles include Managing Director at Exeltis, where revenue grew significantly, and Business Development and M&A Director at Abbott, focusing on strategic partnerships and new product launches. Yann's career also includes senior management positions at Solvay and Fournier Pharma, emphasizing P&L responsibility and operational excellence across various markets. Educational credentials include a Master of Business from IAE Lyon.
This person is not in any offices
Stada Group
14 followers
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.